The Cannabis Market Reaches New Heights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Leerink Affirms GW Pharma (GWPH) at 'Outperform'; Focus Now on LGS Phase III Data
May 5, 2016 12:28 PM EDTLeerink affirms GW Pharma (Nasdaq: GWPH) at Outperform with a price target of $130 following Q1 results reported earlier.
Analyst Paul Matteis offered the following commentary: This morning GWPH reported F2Q16 EPS of £(0.06) versus our estimate of £(0.12) and specified timing of... More
GW Pharma (GWPH) Posts Q1 Loss of 9c/Share
May 5, 2016 7:03 AM EDTGW Pharma (NASDAQ: GWPH) reported Q2 EPS of ($0.09), $1.48 better than the analyst estimate of ($1.57). Revenue for the quarter came in at $3.81 million versus the consensus estimate of $5.99 million.
For earnings history and earnings-related data on GW Pharma (GWPH) click here.
... More